Calliditas Therapeutics AB (Calliditas), a commercial stage biopharma company, announced that they have entered into an exclusive license agreement with Viatris Pharmaceuticals Japan Inc., a subsidiary of Viatris Inc., to register and commercialize Nefecon, a specialty drug recently approved in Europe and the US for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in Japan.
Under the terms of the agreement, Calliditas is entitled receive an initial upfront payment of US$ 20 million upon signing and up to an additional US$ 80 million in pre-defined development and commercialization milestones. Viatris will also pay mid-teens percentage royalties on net sales.
IgAN, also known as Berger
